Ann: Annual Report to Shareholders, page-55

First 55 Last

Share
Profile

Follow
Bazsa

3,968 Posts.

1361

31/10/21

14:10

Post #: 57211645
Share

Originally posted by stockrock: ↑

Traditionally the route to FDA approval for CLBP has been a composite measure of both pain reduction and increase in quality of life score.

what Mesoblast achieved was outstanding reduction in pain, which translated to significantly lower opioid use, but no meaningful improvement in the quality of life score.

So rather than needing to twist the FDA’s arm to argue the quality of life score is no longer relevant, Mesoblast and the FDA could be working together to pivot the results into the new Opioid sparing route of approval rather than the traditional CLBP.

Meaning the results generated thus far could either be used as a surrogate for accelerated approval or as data which could be used for approval if a second phase 3 trial using opioid use reduction/abstinence as a primary endpoint, thus eliminating the need for a quality of life score endpoint altogether.

Both of these outcomes, if true, would be massive wins as composite endpoints are notoriously difficult to meet, so finding and agreeing with the FDA that a single endpoint which is strongly linked to what your treatment can achieve makes it a much more relevant and easier trial to succeed in.

Could explain why in his letter he didn’t talk about the pain reduction, only the opioid sparing benefits … but no matter what, he said the guidance was coming shortly, which he didn’t say about any other FDA meeting or feedback… so my guess is that we will get this before the AGM.

Expand

Over on the other board ET has suggested that the data from the CLBP could not be used for Emergency Use Authorisation. This I believe is incorrect information as the opioid epidemic has been declared a public health emergency.

https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx

We wait for the FDA minutes, this could be the first commercial indication.
GOOD LUCK!

MSB Price at posting: $1.59 Sentiment: None Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

What's causing the cost-of-living crisis, and how to navigate it

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

M4M

Macro, Norden set up transport solutions initiative for West Pilbara